News - ViroMissile

ViroMissile - IDOV Platform - engineered smart virus for cancer

Press Releases

ViroMissile Completes First Dose Cohort of Phase I Trial of Intravenously-Dosed IDOV-2; Safety Review Committee Clears Advancement to Next Cohort

SAN DIEGO — Oct. 1, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the completion of the first dose cohort…

vip_vmOctober 1, 2026

Press Releases

ViroMissile IDOV-Safe Phase 1 Data to Be Presented at the 2026 ASCO Annual Meeting

IDOV-Safe demonstrates efficient intravenous delivery, manageable safety, and encouraging anti-tumor activity in heavily pretreated patients with pMMR/MSS metastatic colorectal cancer, supporting further evaluation in a Phase 2 study SAN DIEGO…

vip_vmMay 27, 2026

Press Releases

ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance

Study examines the safety and early efficacy of an oncolytic virus via a single intravenous dose SAN DIEGO — February 17, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering…

vip_vmFebruary 17, 2026

Michael Wood - Chief Business Officer, ViroMissile

Press Releases

ViroMissile Appoints Michael G. Wood as Chief Business Officer

SAN DIEGO — January 21, 2026 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Michael G. Wood as…

vip_vmJanuary 21, 2026

ViroMissile IDOV platform: targeted anti-tumor viral therapeutics

Press Releases

ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors

Study examines the safety and early efficacy of an oncolytic virus via a single intravenous dose SAN DIEGO — December 11, 2025 — ViroMissile, Inc., a cancer immunotherapy company pioneering…

vip_vmDecember 11, 2025

Press Releases

ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer

SAN DIEGO — December 4, 2025 — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOVTM (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark Bertagnolli as Chief…

vip_vmDecember 4, 2025

Press Releases

ViroMissile honored by Life Sciences Review

SAN DIEGO -- ViroMissile was recognized by "Life Sciences Review" magazine as the Top Cancer Destroying Platform 2025. A pioneering biotech firm headquartered in San Diego, ViroMissile is transforming the landscape of…

vip_vmMay 7, 2025